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ABSTRACT Sex chromosome evolution is accompanied by significant divergence in morphology and gene content 
and results in most genes of one of the sex chromosomes being present in two dosages in one sex and in one dos-
age in the other. To eliminate the difference in the expression levels of these genes between sexes and to restore 
equal expression levels of the genes between sex chromosomes and autosomes, mechanisms of dosage compensa-
tion have appeared. Studies of three classical objects, Drosophila melanogaster, Caenorhabditis elegans, and mam-
mals, have shown that dosage compensation of X-linked genes can be achieved through completely different 
chromosome-wide mechanisms. New data on sex chromosome gene expression demonstrating that many sex 
chromosome genes can be expressed at different levels in males and females were recently obtained from birds 
and butterflies. In this review, dosage compensation mechanisms in D. melanogaster, C. elegans, and mammals 
are considered and the data on sex chromosome gene expression in birds and butterflies, and their influence on 
our view of dosage compensation, are discussed.
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COEVOLUTION OF SEX CHROMOSOMES AND 
DOSAGE COMPENSATION MECHANISMS
In a variety of organisms, sex correlates with a distinct 
sex chromosome set. In particular, in Drosophila mela-
nogaster, as well as in most mammals, females have two 
X-chromosomes, while males are heterogametic with 
two different sex chromosomes, X and Y. Nonetheless, 
the systems determining sex in D. melanogaster and 
mammals are completely different. In D. melanogaster, 
sex depends on the ratio between doses of X-linked and 
autosomal genes [1], whereas in mammals the presence 
of the Y-chromosome, rather the Sry gene responsible 
for male sex determination, is crucial [2]. In contrast, in 
birds, butterflies, and some reptiles, females are het-
erogametic (chromosomes Z and W), while males have 
two Z-chromosomes. The sex chromosomes X and Y, 
as well as Z and W, considerably differ from each oth-
er in size, morphology, and gene content (Fig. 1). The 
chromosomes Y and W are heterochromatinized and 
mainly composed of tandem DNA repeats, and their 
gene content is poor in comparison with that of X- and 
Z-chromosomes.
It is thought that X- and Y-chromosomes appeared 
independently in different taxa and originated from 
a pair of homologous autosomes. The first step in sex 
chromosome evolution was the development of a ge-
netic system of sex determination in a population of 
hermaphrodites or individuals whose sex is deter-
mined by temperature. The most consistent is an order 
of events with initial mutation leading to the appear-
ance of a recessive gene of male sterility on the future 
X-chromosome, followed by the appearance of a domi-
nant gene of female sterility on the future Y-chromo-
some. This resulted in the suppression of recombination 
between the X- and Y-chromosomes at the loci, which 
enabled the linkage of the genes responsible for male 
or female sex determination. The following step was 
the accumulation of genes beneficial to males (but de-
creasing the female’s fitness) on the Y-chromosome. 
The necessity of a tight linkage between these genes 
males   females 
X X Y X Z Z Z W
males   females 
Fig. 1. XY and 
ZW sex chromo-
some systems.
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and the Y-chromosome resulted in the suppression of 
recombination between the X- and Y-chromosomes in 
new loci and gradual expansion of the nonrecombin-
ing region. Suppression of recombination led to the 
accumulation of mutations and deletions in Y-linked 
genes, which are not associated with the formation of 
male features, thereby resulting in their degradation. 
Finally, the entire Y-chromosome could be lost, which 
probably occurred in Caenorhabditis elegans males that 
only possess the X-chromosome. A similar process is 
likely to have resulted in the divergence of Z- and W-
chromosomes [3, 4].
To compensate for such an essential loss of genes on 
the Y-chromosome, natural selection might have fa-
vored mechanisms that elevated the expression of X-
linked genes in males [5]. Up-regulation of the genes 
localized on the single X-chromosome in males has been 
known for a long time and is well-studied in D. mela-
nogaster [6]. A similar path of restoring the X-linked 
gene expression level (dosage compensation) was pro-
posed for mammals and C. elegans, but convincing ar-
guments took a long time to emerge. A hypothesis on X-
chromosome up-regulation in mammal and C. elegans 
males was recently confirmed thanks to the develop-
ment of microarray techniques. This method allowed to 
determine the mean expression level of autosomal and 
X-linked genes, which was found to be equal in males 
of both mammals and C. elegans [7–9].
An increase in the transcription level of X-linked 
genes might result in an excess of their products in 
females. However, studies on gene expression using 
microarray have shown that X-linked genes are ex-
pressed in females of D. melanogaster, C. elegans, and 
mammals at the same level as autosomal genes [7–9]. 
Hence, females should also possess the mechanism(s) 
supporting the transcription balance between the X-
linked and autosomal genes, as well as an equal expres-
sion level of the X-linked genes in both sexes. Despite 
the fact that it has a similar origin, dosage compensa-
tion of X-linked genes occurs in different ways in D. 
melanogaster, C. elegans, and mammals (Fig.2). In D. 
melanogaster, dosage compensation only occurs in 
males, while in females the expression levels of genes 
localized on the autosomes and both X-chromosomes 
are equal [7]. In C. elegans, the single X-chromosome in 
males and both X-chromosomes in hermaphrodites are 
up-regulated. The restoration of the transcription bal-
ance in hermaphrodites is achieved by a specific mech-
anism that partially down-regulates gene expression on 
both X-chromosomes [7]. In mammals, gene expression 
is up-regulated on the X-chromosome in males and one 
of the two X-chromosomes in females. On the second 
X-chromosome, transcription of most genes is com-
pletely repressed; i. e., this X-chromosome undergoes 
inactivation [7, 8]. The mechanisms underlying these 
processes deserve a more detailed examination.
DOSAGE COMPENSATION OF X-LINKED 
GENES IN D. melanogaster
The elevated level of expression of X-linked genes in 
D. melanogaster males is supported by a complex com-
posed of six proteins: MSL1 (male-specific lethal 1), 
MSL2, MSL3, MOF (males absent on the first), MLE 
(maleless), and JIL1 (Janus kinase 1), and two noncod-
ing RNAs: roX1 and roX2 (RNA on the X). The key ele-
ment for the assembly of this complex is MSL2, which 
is only synthesized in males. The MSL2 protein is absent 
in females, so other components cannot form the dos-
age compensation complex. According to the generally 
accepted model, MSL2 stabilizes MSL1 by direct inter-
action, thus forming a platform for further assembly 
of the dosage compensation complex [10]. The proteins 
MOF and JIL1 are responsible for the activation of X-
linked gene transcription in males. The MOF protein 
acetylates histone H4 at Lys16 (H4K16). This modifi-
cation is characteristic of the transcriptionally active 
chromatin and specific for the male X-chromosome 
[11, 12]. However, recent data suggest that MOF can 
acetylate H4K16 not only on the X-chromosome, but 
also on the autosomes of both sexes [13]. MOF has been 
found to interact not only with the MSL complex, but 
also with the so-called NSL (nonspecific lethal) com-
plex that binds to promotors of transcriptionally active 
autosomal genes in males as well as autosomal and sex-
D. melanogaster   C. elegans   mammals
males 
females
hermaphrodites
A
A A X X X X X X A A A A
A X X X Y Y A A A A
autosomal expression level 
X-chromosome up-regulation 
X-chromosome inactivation 
partial down-regulation of both X-chromosomes
Y-chromosome 
Fig. 2. Diversity of X-linked gene dosage compensation 
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chromosomal genes in females. Hence, MOF, via inter-
action with different protein complexes, is implicated in 
two processes: dosage compensation of X-linked genes 
in males and general regulation of gene transcription in 
D. melanogaster [14, 15]. Moreover, homologues of MOF 
and the NSL complex exist in mammals, in which they 
play the same role in the histone H4 acetylation [16, 
17]. These facts suggest that the mechanism of dosage 
compensation in D. melanogaster did not appear de novo 
but was formed on the basis of existing proteins which 
could retain their initial functions. JIL1 kinase is freely 
associated with the MSL complex and phosphorylates 
histone H3 at Ser10. This modification is also implicated 
in the formation of transcriptionally active chromatin, 
likely counteracting the binding of the heterochromatin 
protein HP1 [18, 19]. Thus, up-regulation of X-linked 
genes in D. melanogaster is achieved through the crea-
tion of an “open” incompact chromatin structure acces-
sible to transcription factors [20]. RNA-DNA-helicase 
MLE is thought to promote the integration of roX1 and 
roX2 RNAs into the dosage compensation complex [10]. 
These RNAs are interchangeable and essential for the 
binding of the dosage compensation complex with the 
X-chromosome [21]. Interestingly, the human homo-
logue of the MSL complex does not contain the roX1 
and roX2 RNAs. So, the recruitment of these noncoding 
RNAs into the MSL complex might be the turning point 
in the formation of the dosage compensation mecha-
nism in D. melanogaster [22].
The X-chromosome of D. melanogaster has no less 
than 150 specific sites, called chromatin entry sites, 
which contain MSL recognition elements for the bind-
ing of the dosage compensation complex. Following 
the binding of these sites, the MSL complex spreads 
along the X-chromosome and interacts with actively 
transcribed genes [23]. Epigenetic features, such as 
trimethylated H3K36 (a characteristic of transcribed 
genes), rather than nucleotide sequences, are most 
likely significant at this stage [24]. Nevertheless, not all 
transcriptionally active genes of the D. melanogaster 
male X-chromosome bind the dosage compensation 
complex. Moreover, binding of the MSL complex not 
always leads to exactly a twofold increase in the X-
linked gene expression level. In some cases, the level 
of transcription remains virtually unchanged [25–27]. 
Therefore, the mechanism controlling the expression 
level of individual X-linked genes in D. melanogaster 
males has yet to be identified.
The mechanism underlying up-regulation of X-
linked genes in mammalian and C. elegans males re-
mains unknown. It is likely to be supported by epige-
netic mechanisms as in D. melanogaster. However, it 
is worth noting that no significant difference has been 
found between the chromatin structures of the X-
chromosome and autosomes. So, the X-chromosome 
up-regulation in males may be a result of alterations in 
the nucleotide sequences of the gene regulatory regions 
that took shape during evolution [8, 28]. Besides, there 
is another possible way of enhancing X-linked gene ex-
pression in mammals. The fact is that the genes of the 
active and inactive X-chromosomes differ in methyla-
tion patterns. The alleles of the inactive X-chromosome 
are hypermethylated at the CpG-dinucleotides of pro-
motor regions, which matches their inactivation. At 
the same time, the alleles of the active X-chromosome 
in females and genes of the X-chromosome in males 
are hypermethylated at the CpG-dinucleotides of gene 
bodies [29]. However, it remains absolutely unclear how 
methylation of gene bodies can lead to elevated expres-
sion of X-linked genes in mammals.
DOSAGE COMPENSATION  
OF X-LINKED GENES IN C. elegans
As mentioned above, dosage compensation of the  C. 
elegans X-linked genes includes two processes: X-
linked gene up-regulation in males and partial repres-
sion of the genes localized on both X-chromosomes in 
hermaphrodites. While the mechanism of the first 
process is absolutely unknown, the complex of dos-
age compensation composed of nine proteins SDC-1, 
SDC-2, SDC-3, DPY-21, DPY-26, DPY-27, DPY-28, 
DPY-30, and MIX1 has been characterized in  C. el-
egans hermaphrodites [30]. Three proteins (DPY-26, 
DPY-27, and DPY-28) closely resemble the proteins 
of the 13S condensin complex responsible for chro-
mosome compaction in mitosis and meiosis not only 
in C. elegans, but also in other eukaryotes. Another 
protein, MIX1 (mitosis and X-associated protein 1), 
is common to both complexes [31–34]. However, not 
only MIX1 has a dual function. The protein DPY-28 
controls the number and distribution of crossovers be-
tween homologous chromosomes in meiosis [35]. DPY-
30 is part of a complex that is homologous to the yeast 
complex Set1/COMPASS methylating histone H3. 
DPY-30 is likely implicated in both dosage compen-
sation and the general regulation of gene transcrip-
tion in C. elegans males and hermaphrodites [36, 37]. 
An important role in the assembly and function of the 
dosage compensation complex is played by the protein 
SDC-2 (sex determination and dosage compensation 
2). Unlike other proteins, SDC-2 is only expressed in 
hermaphrodites and seems to be responsible for the 
specific impact of the dosage compensation complex 
on the X-chromosome, because it can bind to the X-
chromosome independently of other components of 
the complex [38]. The complex assembly begins with 
the interaction between SDC-2, SDC-3, and DPY-30, 
which creates a platform for the binding of all other REVIEWS
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proteins to the X-chromosome [39–41]. Interestingly, 
the same complex (except for DPY-21) is implicated 
in a 20-fold transcription repression of the autosomal 
gene her-1 (hermaphrodization of X0 animals), which 
is responsible for male sex determination [38, 41]; i.e. 
this complex participates not only in the dosage com-
pensation of X-linked genes, but also in the sex deter-
mination system.
To bind to the dosage compensation complex there 
are specific nucleotide sequences on the C. elegans X-
chromosome, but their density is significantly lower 
than that on the D. melanogaster X-chromosome (~40 
and 150, respectively). These sequences are divided into 
two types: the rex- and dox-sites. Rex (recruitment ele-
ments on X)-sites can bind to the dosage compensation 
complex regardless of whether they are localized on 
the X-chromosome or autosomes and are most likely 
responsible for the primary recognition of the com-
plex. Dox (dependent on X)-sites only interact with the 
dosage compensation complex when localized on the 
X-chromosome, and they are mainly implicated in the 
spreading of the complex along the X-chromosomes of 
C. elegans hermaphrodites [42].
The mechanism of dosage compensation complex-
dependent partial repression of X-linked gene expres-
sion in hermaphrodites is not yet known; however, a 
certain similitude between the C. elegans dosage com-
pensation and the 13S condensin complexes allows to 
assume that the same principle underlies both the tran-
scription repression of X-linked genes and the chro-
mosome condensation in mitosis and meiosis [37]. The 
similarity to the 13S condensin complex and the dual 
function of some proteins of the dosage compensation 
complex suggest that in both C. elegans and D. mela-
nogaster dosage compensation appeared due to the ac-
quisition of novel functions by existing proteins, rather 
than the development of an absolutely new mechanism. 
Which X-linked genes are subjects to dosage compen-
sation in C. elegans hermaphrodites (and to what ex-
tent) remains unknown.
DOSAGE COMPENSATION OF X-LINKED 
GENES IN MAMMALS
Like C. elegans, mammals demonstrate up-regulation 
of X-linked genes in both sexes. The restoration of the 
gene transcription balance in females is achieved by 
transcription repression (inactivation) of the majority 
of genes localized on one of the two X-chromosomes 
[43]. X-inactivation may be either random or imprinted 
[28]. When X-inactivation is imprinted, the paternally 
inherited X-chromosome is predominantly inactivated. 
This variant of inactivation occurs in marsupials as well 
as in the extraembryonic tissues of some eutherians. 
When the inactivation is random, the chances of the 
paternal and maternal X-chromosomes being inacti-
vated are equal. This type of X-inactivation takes place 
in somatic tissues of eutherians.
The eutherian X-chromosome has a specific lo -
cus called the X-inactivation center. One gene from 
this locus, Xist, is the key gene in the initiation of 
the X-inactivation process. It encodes a noncoding 
RNA, which then spreads along the further inactive 
X-chromosome, which leads to a series of epigenetic 
changes [28, 44–46]. As a result, RNA polymerase II is 
excluded from the inactive X-chromosome, and chro-
matin-modifying complexes appear. Consequently, the 
inactive X-chromosome loses modifications that are 
characteristic of transcriptionally active chromatin, 
such as histone H3 dimethylated at Lys4 (Н3К4) and 
acetylated histones H3 and H4. Instead, the inactive 
X-chromosome gains modifications characteristic of 
transcriptionally inactive chromatin, such as histone 
H3 trimethylated at Lys27 (Н3К27), histone H2A ubiq-
uitinylated at Lys119 (uH2A), histone H3 dimethyl-
ated at Lys9 (Н3К9), and histone H4 monomethylated 
at Lys20 (Н4К20). In addition, the inactive X-chromo-
some becomes late-replicating and associates with a 
histone H2A variant (macroH2A) containing a nonhis-
tone domain. The last epigenetic event in the X-inacti-
vation process is methylation at X-linked gene promo-
tor regions, which allows to maintain the stability of 
the inactive state of the X-chromosome. Complexes of 
polycomb proteins are implicated in the establishment 
of the inactive state of the X-chromosome in mam -
malian females. PRC1 (polycomb repressor complex 
1) is responsible for the ubiquitinylation of histone 
H2A [47, 48], while PRC2 is responsible for Н3К27 tri-
methylation [49, 50]. However, these complexes are 
not specific to females, as they are also implicated in 
the repression of both X-linked and autosomal genes 
[22]. The enzymes fulfilling Н3К9 dimethylation and 
Н4К20 monomethylation have not been known pre-
cisely. It is believed that they are methyltransferase 
G9a and PR-Set7, respectively [51, 52]. It is worth not-
ing that noncoding RNAs and chromatin-modifying 
complexes are involved in the dosage compensation of 
X-linked genes both in mammals and D. melanogaster, 
but their effects on gene expression are diametrical-
ly opposite. The question of how Xist RNA interacts 
with chromatin-modifying factors still remains open. 
Moreover, the gene Xist was not found in marsupials 
[53], despite the fact that their chromatin modification 
patterns on the inactive X-chromosome closely resem-
ble those in eutherians. It becomes obvious that both 
the X-inactivation center and random X-inactivation 
only developed in eutherians [53, 54], and that the X-
inactivation process in marsupials differs from that in 
placental mammals.40 | ACTA NATURAE |  VOL. 2  № 4 (7)  2010
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In its mechanism, X-inactivation is similar to the im-
printing of autosomal genes. In both cases, noncoding 
RNAs are involved whose expression leads to the es-
tablishment of the same chromatin modifications: hy-
pomethylated Н3К4, hypoacetylated Н3К9, trimeth-
ylated Н3К27, uH2A, dimethylated Н3К9, and DNA 
methylation [55, 56]. The final result of both processes is 
the transcription repression of one of two alleles. Hence, 
the method of gene transcription repression during X-
inactivation in mammalian females is not unique; the 
same mechanism is also at play in the establishment of 
monoallele expression for certain autosomal genes.
It is worth noting that not all genes of the inac -
tive X-chromosome undergo inactivation. Studies on 
the expression status of human X-linked genes have 
shown that 15% of genes always escape X-inactiva-
tion, while 10% of genes have heterogeneous expres-
sion; i.e., they undergo X-inactivation in some wom-
en and escape X-inactivation in others [57]. Besides, 
genes escaping X-inactivation were found in mice and 
some other mammals [58, 59]. However, the reason 
why some X-linked genes escape X-inactivation is as 
yet unknown. In some cases, this may be explained by 
the presence of a Y-chromosomal homologue of an X-
linked gene. In this case, escaping X-inactivation ena-
bles the restoration of equal X-linked gene expression 
between the sexes. Nonetheless, many X-linked genes 
escaping X-inactivation have no Y-homologues. It is 
possible that a higher expression level of these genes 
in females is associated with the formation of female-
specific features [60, 61]. Interestingly, the expression 
level of many genes escaping X-inactivation on the in-
active X-chromosome is much lower than that on the 
active X-chromosome [8, 9, 57]. This suggests that a 
higher expression level of these genes in females is of 
little importance. It is also possible that an imbalance 
of X-linked genes can be evened out after transcrip-
tion [60, 61].
It has been suggested that special elements are nec-
essary for the effective spreading of the inactive state 
along the X-chromosome. The most likely candidates 
are long, interspersed nuclear elements (LINEs) [62]. 
This hypothesis is supported by the fact that murine 
and human X-chromosomes are twice richer in LINEs 
as compared to autosomes. It is worth noting that the 
distribution of LINEs on the human X-chromosome 
correlates with gene expression status. The highest 
density of LINEs is observed in the X-inactivation cent-
er and in regions of gene inactivation. Conversely, the 
density of LINEs in regions that escape X-inactivation 
is lower [57, 63, 64]. Yet, what are the sequences neces-
sary for effective spreading of the inactive state along 
the X-chromosome and what are the mechanisms of 
their action remains unknown.
COMMON FEATURES OF X-LINKED GENE 
DOSAGE COMPENSATION SYSTEMS
Examination of three model objects (D. melanogaster, C. 
elegans, and mammals) demonstrates that X-linked gene 
dosage compensation can occur via a variety of mecha-
nisms. The difference in dosage compensation mecha-
nisms appears to reflect an independent origin of sex 
chromosomes in these species and, as a result, independ-
ent formation of the mechanisms directed toward the 
regulation of X-linked gene expression. Despite the dif-
ference in means of X-linked gene dosage compensation 
in D. melanogaster, C. elegans, and mammals, there are 
several common features. First, dosage compensation is 
achieved via mechanisms operating at the chromosomal 
level; these mechanisms do not appear de novo: existing 
proteins and protein complexes adapt to the regulation of 
X-linked gene expression. Second, up-regulation of the 
single X-chromosome in males is common to all three dos -
age compensation systems, though the mechanisms un-
derlying this phenomenon may differ. Third, the required 
gene expression level is supported via a change in the X-
chromosomal chromatin structure by chromatin-modi-
fying complexes. In D. melanogaster and mammals, the 
effect of chromatin-modifying complexes in the course of 
X-linked gene dosage compensation is associated with the 
expression of noncoding RNAs. Tight association between 
the noncoding RNAs and regulation of gene expression 
implies that noncoding RNA is likely to be also found in 
the C. elegans dosage compensation system. Fourth, the 
X-chromosome contains a set of sequences responsible 
for binding and effective spreading of the dosage com-
pensation complexes. Thus, the mechanisms of dosage 
compensation enable the leveling of the expression of au-
tosomal and X-linked genes, as well as maintenance of 
an equal expression level of X-linked genes in both sexes. 
Transcriptional balance of X-linked genes is supported in 
different somatic cell types and the germinal cells of D. 
melanogaster and mammals in both sexes [7, 8], thus sug-
gesting its importance to the organism.
DOSAGE COMPENSATION OF Z-LINKED 
GENES IN BIRDS AND BUTTERFLIES
By analogy with the XY system of sex chromosomes, 
one might expect that the ZW system of sex chromo-
somes should also be characterized by the up-regula-
tion of genes on the single Z-chromosome in females 
(heterogametic sex). However, early studies on the ex-
pression of a small number of Z-linked genes in birds 
and butterflies showed an elevated expression of some 
Z-linked genes in males, as compared to females [65–
68]. Thus, the existence of Z-linked gene dosage com-
pensation was called into doubt for a long time.
The use of microarray techniques allowed to deter-
mine the level of Z-linked and autosomal gene expres-REVIEWS
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sion in two avian species (chicken and zebra-finch) 
and in silkworm. The ratio between male and female 
Z-linked gene expression levels in birds ranged be-
tween 1 and 2: i.e., one gets the impression that the Z-
chromosome is between dosage compensation at the 
chromosomal level and the lack of dosage compensa-
tion [69, 70]. Similar data was obtained from the study 
of Z-linked gene expression in silkworm [71]. Moreo-
ver, in zebra-finch, Z-linked genes were distinctly di-
vided into two groups: genes with an equal expression 
level in both sexes and those with a higher expression 
level in males [69]. Birds and butterflies do not appear 
to have mechanisms controlling the gene expression 
of the whole Z-chromosome; however, some Z-linked 
genes in females do undergo dosage compensation 
(Fig.3). The mechanisms involved in this process are 
not yet understood. Nonetheless, a specific locus, MHM 
(male hypermethylated), has been found on the avian 
Z-chromosome. This locus is hypermethylated in males, 
while in females a noncoding RNA is transcribed from 
this locus and accumulates in the region surrounding 
MHM. In females, this region is acetylated at Lys16 of 
histone H4 (H4K16). Besides, despite the genes under-
going dosage compensation being distributed along the 
Z-chromosome, the majority of them are concentrat-
ed near the MHM locus. It is likely that Z-linked gene 
dosage compensation in birds occurs the same way it 
does in D. melanogaster: noncoding RNA and Н4К16 
acetylation provide an elevated expression level of Z-
linked genes in females [72].
The difference in the degrees of dosage compensa-
tion between the X- and Z-chromosomes might be as-
cribed to their age. When sex chromosomes are young 
enough, the mechanisms controlling gene expression 
might not have developed yet. While avian and mam-
malian sex chromosomes are close in age (no less than 
150 and 166 MYA, respectively), the sex chromosomes 
of D. melanogaster are relatively young (~65 MYA), but 
the age is enough in order for the chromosomal dosage 
compensation mechanism to have developed. Hence, 
the age of sex chromosomes does not influence the ex-
tent of dosage compensation [22, 73]. It is known that 
hemizygosity at several genes or small genomic regions 
may remain, with no consequences for the organism. 
The avian and butterfly Z-chromosomes contain about 
840 and 600 genes, respectively, which is considerably 
less than the number of genes on the D. melanogaster, 
C. elegans, and human X-chromosomes (2,300; 3,100; 
and 1,100 genes, respectively). It is likely that it is the 
lower number of genes on the sex chromosomes of 
birds and butterflies that allows them to do without 
chromosomal dosage compensation mechanisms. How-
ever, hemizygosity at several hundred genes must be 
lethal anyway; so the limited dosage compensation in 
birds and butterflies cannot be the result of lower gene 
density on sex chromosomes [22, 73]. As of now, the lo-
cal dosage compensation is only found in species whose 
heterogametic sex is female (ZW). Since the Z-linked 
gene expression level was only examined in representa-
tives of two taxa, it remains unclear whether this path 
of dosage compensation is characteristic of organisms 
with the ZW sex chromosome system or whether it is 
a coincidence. The study of other taxa, whose hetero-
gametic sex is female, will likely answer this question 
[22, 73].
CONCLUSION
The data on sex-chromosomal gene expression in birds 
and butterflies force us to look anew at the problem of 
gene dosage compensation. It is becoming obvious that 
sex-chromosomal genes undergo dosage compensation 
to different extents, up to its complete escaping. It is 
possible that dosage compensation mechanisms evolved 
to control the expression of a distinct gene set, rather 
than the entire sex chromosome. This postulate seems 
to be correct not only for the Z-chromosome, but also 
for the X-chromosome, because genes escaping dosage 
compensation were found in mammals and D. mela-
nogaster. Further studies will probably focus on the 
identification of the sex-chromosomal genes requiring 
dosage compensation, as well as on the mechanisms 
that determine the extent of dosage compensation for 
individual genes. Another important line of inquiry 
may be uncovering the mechanisms underlying the 
up-regulation of the X-linked genes in mammals and 
C. elegans. Studies on heteromorphic sex chromosomes 
in new taxa could shed light on the matter. 
This study was supported by the RAS Presidium 
Program Molecular and Cell Biology. 
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